Purpose: The aim of this study was to examine the relationship between subclinical diabetic macular edema (SCME) and the development of central-involved macular edema (CIME) in patients with diabetes mellitus type-2 and mild nonproliferative diabetic retinopathy (NPDR), from 2 populations of different ethnicities. Methods: Two hundred and five patients with diabetes mellitus type-2 and mild NPDR with no prior laser or intravitreal treatment were followed for 2 years or until the development of CIME. Ophthalmological examinations, including BCVA, fundus photography with RetmarkerDR analysis, and optical coherence tomography were performed at baseline and months 6, 12, and 24. Results: One hundred and fifty eight eyes/patients reached either the study endpoint, CIME (n = 24), or performed the 24-month visit without developing CIME (n = 134). Fifty eyes/patients had SCME at baseline (31.6%). Of these 50 eyes, 16 (32.0%) developed CIME, whereas of the 108 eyes with normal retinal thickness (RT) at baseline, only 8 (7.4%) developed CIME (p < 0.001). Patients with increased RT in the central subfield at baseline showed a 12-fold risk of progression to CIME compared with patients without SCME. Conclusions: In patients with mild NPDR, the presence of SCME is a good predictor of progression to CIME.

Keywords:
Biomarkers, Diabetes, Macular edema, Nonproliferative diabetic retinopathy
1.
Brown J, Solomon S, Bressler S, Schachat A, DiBernardo C, Bressler N: Detection of diabetic foveal edema. Arch Ophthalmol 2004; 122: 330–335.
2.
Browning DJ, Fraser CM: The predictive value of patient and eye characteristics on the course of subclinical diabetic macular edema. Am J Ophthalmol 2008; 145: 149–154.
3.
Bressler NM, Miller KM, Beck RW, Bressler SB, Glassman a R, Schlossman DK: Observational study of subclinical diabetic macular edema. Eye (London) 2012; 26: 833–840.
4.
Ribeiro L, Pappuru R, Lobo C, Alves D, Cunha-Vaz J: Different phenotypes of mild nonproliferative diabetic retinopathy with different risks for development of macular edema (C-TRACER Study). Ophthalmic Res 2018; 59: 59–67.
5.
Chalam K V, Bressler SB, Edwards AR, Berger BB, Bressler NM, Nielsen JS: Retinal thickness in people with diabetes and minimal or no diabetic retinopathy: Heidelberg Spectralis optical coherence tomography. Invest Ophthalmol Vis Sci 2012; 53: 8154–8161.
6.
Pires I, Santos AR, Nunes S, Lobo C, Cunha-Vaz J: Subclinical macular edema as a predictor of progression to clinically significant macular edema in type 2 diabetes. Ophthalmologica 2013; 230: 201–206.
7.
Friedman SM, Almukhtar TH, Baker CW, Glassman AR, Elman MJ, Melia M: Topical NEPAFENEC in eyes with noncentral diabetic macular edema. Retina 2015; 35: 944–956.
8.
Nunes S, Pires I, Rosa A, Duarte L, Bernardes R, Cunha-Vaz J: Microaneurysm turnover is a biomarker for diabetic retinopathy progression to clinically significant macular edema: findings for type 2 diabetics with nonproliferative retinopathy. Ophthalmologica 2009; 223: 292–297.
9.
Nunes S, Ribeiro L, Lobo C, Cunha-Vaz J: Three different phenotypes of mild nonproliferative diabetic retinopathy with different risks for development of clinically significant macular edema. Investig Opthalmology Vis Sci 2013; 54: 4595.
10.
Haritoglou C, Kernt M, Neubauer A, Gerss J, Oliveira CM, Ulbig M: Microaneurysm formation rate as a predictive marker for progression to clinically significant macular edema in nonproliferative diabetic retinopathy. Retina 2014; 34: 157–164.
11.
Lobo CL: Three-year follow-up study of blood-retinal barrier and retinal thickness alterations in patients with type 2 diabetes mellitus and mild nonproliferative diabetic retinopathy. Arch Ophthalmol 2004; 122: 211.
12.
Cunha-Vaz J, Bernardes R, Lobo C: Blood-retinal barrier. Eur J Ophthalmol 2011; 21: 3–9.
13.
Cunha-Vaz J, Santos T, Ribeiro L, Alves D, Marques I, Goldberg M: OCT-leakage: a new method to identify and locate abnormal fluid accumulation in diabetic retinal edema. Invest Ophthalmol Vis Sci 2016; 57: 6776–6783.
14.
Santos A, Costa M, Schwartz C, Alves D, Figueira J, Cunha-Vaz JG: OCT baseline predictors for initial BCVA response to intravitreal anti-VEGF treatment in eyes with diabetic macular edema: the CHARTRES study. Retina 2017 Epub ahead of print.
15.
Santos A, Alves D, Santos T, Figueira J, Silva R, Cunha-Vaz J: Measurements of retinal fluid by OCT-leakage in diabetic macular edema: a biomarker of visual acuity response to treatment. Retina 2017, Epub ahead of print.
© 2018 S. Karger AG, Basel
2018
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.